Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 199-206 , August 1999

Second-line chemotherapy and its evaluation in small cell lung cancer

  • C. Huisman

      Affiliations

    • Departments of Pulmonary Diseases and Medical Oncology
    • ,
  • P.E. Postmus

      Affiliations

    • Departments of Pulmonary Diseases and Medical Oncology
    • ,
  • G. Giaccone

      Affiliations

    • Departments of Pulmonary Diseases and Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
    • ,
  • E.F. Smit

      Affiliations

    • Departments of Pulmonary Diseases and Medical Oncology

References 

    REFERENCES
  1. Seifter EJ and Idhe DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988;15:278–299
  2. Elias AD. Small cell lung cancer, state-of-the-art therapy in 1996. Chest. 1997;112:251S–258S
  3. Johnson, DH. Treatment of relapsed small cell lung cancer. Lung Cancer, 11
  4. Andersen M, Kristjansen PEG and Hansen HH. Second-line chemotherapy in small cell lung cancer. Cancer Treat Rev. 1990;17:427–436
  5. Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, et al. Small cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med. 1983;98:472–474
  6. Giaccone G, Ferrati P, Donadio M, Testore F and Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23:1697–1699
  7. Postmus PE, Berendsen HH, Van Zandwijk N, Splinter TAW, Burghouts JThM and Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–1411
  8. Giaccone G, Donadio M, Bonardi G, Testore F and Calciati A. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–1270
  9. Johnson DH, Greco FA, Strupp J, Hande KR and Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol. 1990;8:1613–1617
  10. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JThM, et al. Maintenance chemotherapy in small cell lung cancer: long term results of a randomized trial. J Clin Oncol. 1993;11:1230–1240
  11. Giaccone G, Donadio M, Bonardi G, Testore F and Calciati A. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–1270
  12. Smit EF, Fokkema E, Biesma B, Groen HJM, Snoek W and Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer. 1998;77:347–351
  13. Perez-Solar R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM and Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase 1 poison topotecan. J Clin Oncol. 1996;14:2785–2790
  14. Berendsen HH, De Leij L, De Vries, Mesander G, Mulder NH, De Jong B, et al. Characterisation of three small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 1988;48:6891–6899
  15. De Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, De Leij L and Buys CH. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 1989;47:4175–4178
  16. Poupon MF, Arvelo F, Goguel AF, Bourgeais Y, Jacrot M, Hanania N, et al. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst. 1993;85:2023–2029
  17. Moore TD and Korn EL. Phase II trial design considerations for small cell lung cancer. J Natl Cancer Inst. 1992;84:150–154
  18. Grant SC, Gralla RJ, Kris MG, Orazem J and Kitsis EA. Single-agent chemotherapy trials in small-cell lung cancer, 1970–1990: the case for studies in previously treated patients. J Clin Oncol. 1992;10:484–498
  19. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89:577–580
  20. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small cell lung cancer: a stopped multicentre trial. Lancet. 1996;348:563–566
  21. Groen HJM, Fokkema E, Biesma B, Kwa HB, Van Putten J, Postmus PE and Smit EF. Paclitaxel and carboplatin in the treatment of small cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide. A non-cross resistant schedule. J Clin Oncol. 1999;17:927–932
  22. Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, et al. Combination of Irinotecan and Etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol. 1998;16:3329–3334
  23. Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Marsumoto T, Ohmatsu H, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small cell lung cancer. J Clin Oncol. 1997;15
  24. Faylona E, Loehrer P, Einhorn L, Ansari R, McClean J and Williams S. A phase II study of daily oral VP-16 + ifosfamide + cisplatin for previously treated small cell lung cancer: a Hoosier oncology group trial. J Clin Oncol. 1995;13:1209–1214
  25. Einhorn LH and Loehrer PJ. Hoosier oncology group studies in extensive and recurrent small cell lung cancer. Semin Oncol. 1995;22:28–31
  26. Postmus PE, Smit EF, Kirkpatrick A and Splinter TAW. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A:204–207
  27. Falk SJ, Maughan TS, Laurance VM, Lamont A, Boote D, Ford JM, et al. Phase II study of carboplatin and adriamycin as second-line chemotherapy in small cell lung cancer. Clin Oncol. 1993;5:85–88
  28. Albain KS, Crowly JJ, Hutchins L, Gandara D, O’Bryan RM, Von Hoff DD, et al. Predictors of survival following relapse or progression of small cell lung cancer. Cancer. 1993;72:1184–1191
  29. Postmus PE, Smit EF, Berendsen HH and Haaxma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Sem Oncol. 1992;19:17–23
  30. O’Bryan RM, Crowley JJ, Kim PN, Epstein RB, Neilan B, Coltman CA, et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine and cyclophosphamide for salvage treatment in small cell lung cancer. Cancer. 1990;65:856–860
  31. Smit EF, Berendsen HH, De Vries EGE, Mulder NH and Postmus PE. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 1989;25:202–204
  32. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a cancer research trial. Br J Cancer. 1989;59:578–583
  33. Von Pawel, J. Depierre, A. Hans, K. Moro, D. Clark, P. I. Gatzemeier, U. Paillot, N. Scheithauer, W. Carmichael, J. Santoro, A. Ross, G. Hearn S and Marangolo, M. Evaluation of topotecan (hycampthin): in relapsed small cell lung cancer Submitted 1991.
  34. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for treatment of recurrent small cell lung cancer. J Clin Oncol. 1999;17:657–667
  35. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus PE, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol. 1997;15:2090–2096
  36. Perez-Solar R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM and Hong WK. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol. 1996;14:2785–2790
  37. Fusure K, Kubota K, Kawahara M, Takada M, Kimura I, Fuji M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 1996;53:169–172
  38. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H and Kaye SB. Activity of docetaxel (taxotere) in small cell lung cancer. Eur J Cancer. 1994;30A:1058–1060
  39. Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe Ch, Van Glabbeke M, Noseda MA, Gozzelino F, et al. Phase II study of vinorelbine (navelbine) in previously treated small cell lung cancer patients. Eur J Cancer. 1993;29A:1720–1722
  40. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229
  41. Tummarello D, Guidi F, Torresi U, Dazzi C and Cellerino R. Teniposide (VM-26) as second-line treatment for small cell lung cancer. Anticancer Res. 1990;10:397–400
  42. Tummarello D, Guidi F, Di Furia L, Gramazio A, Menichetti E and Cellerino R. A phase II study with teniposide (VM-26) in patients with progressed or relapsed small cell lung cancer. J of Chemother. 1989;1:64–67

☆ Address for correspondence and reprint requests: E.F. Smit, MD PhD, Department of Pulmonary Diseases, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Tel: +31 20 4444782 Fax: +31 20 4444328 E-mail: ef.smit@azvu.nl

PII: S0305-7372(99)90125-1

doi: 10.1053/ctrv.1999.0125

Cancer Treatment Reviews
Volume 25, Issue 4 , Pages 199-206 , August 1999

Article Tools